|
|
|
|
|
|
|
|
|
|
|
|
|
20.05.25 - 14:03
|
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat during the Alliance Global Partners (“A.G.P.”) Virtual Annual Healthcare Company Showcase, taking place May 21, 2025....
|
|
|
|
|
|
|
|
|
09.05.25 - 22:09
|
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.03.25 - 13:03
|
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time....
|
|
|
14.03.25 - 12:24
|
FDA clears PDS Biotechnology’s Versamune MUC1 combo for mCRC (PBR)
|
|
|
Versamune is the company's new investigational MUC1-targeted immunotherapy candidate. The therapy is intended for individuals who have failed prior treatments. PDS submitted the application to the US regulator
The post FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC appeared first on Pharmaceutical Business review....
|
|
|
|
|
11.03.25 - 13:03
|
PDS Biotech Leadership to Participate in March Conferences (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
